Advertisement

Topics

Search Results for "Arbonne Annual Revenue 2012"

18:03 EDT 25th May 2017 | BioPortfolio

Matching Channels

macitentan

Macitentan (Opsumit®) is a novel dual endothelin receptor antagonist (ERA) that resulted from a tailored drug discovery process with the target to develop an ERA optimized for efficacy and safet...

Medtronic

With annual sales reaching $15 billion in 2010, Medtronic is the 4th largest medical devices company in the world (based on annual sales). The device portfolio of Medtronic is broad; covering card...

ATX-MS-1467 for patients with multiple sclerosis (MS)

ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the ...

Rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic systemic disease characterized by progressive joint deformity and joint destruction driven by synovial inflammation and hyperplasia in which cytokines play cen...

GE Healthcare

Ranked as the third largest medical device company in the world (based on annual sales), GE Healthcare generates $16 billion in sales each year. GEs' area of expertise is the imaging that is i...

Matching News

Cynosure Achieves Record Quarterly Revenue of $122. ...

Full-Year 2016 Highlights: Record annual revenue of $433.5 million, up 28 percent year-over-year GAAP earnings of $0.65per diluted share includes $7.2 millioncharge Read more...

Myriad Genetics Increases Annual Revenue Guidance, Narrows Adj. EPS Guidance

WASHINGTON (dpa-AFX) - Myriad Genetics, Inc. (MYGN) announced the company now expects fiscal 2017 revenue to be in a range of $763-$765 million, and adj. EPS of $1.01-$1.03. For fourth-quarter, th...

Vertex Pharmaceuticals revenue outlook for cystic fibrosis treatments

Jan 8 Vertex Pharmaceuticals Inc said on Sunday that it expected full-year 2017 revenue from its Orkambi cystic fibrosis treatment of $1.1 billion to $1.3 billion and revenue from its Kalydeco treatme...

Iridex reports $10.5 million in quarterly revenue

Iridex reported revenue of $10.5 million in the first quarter of 2017 compared with revenue of $11.9 million in the same time period last year, according to a company press release.The 12% decrease wa...

Octapharma AG Publishes 2016 Annual Results Reporting Revenue Of ???1.6 Billion And Operating Income Of ???383 Million

  Life Sciences Jobs   ...

Virbac: annual sales growth of 4.5%, at constant exchange rates

Virbac: annual sales growth of 4.5%, at constant exchange rates Public release - January 17th, 2017 Virbac consolidated revenue in the fourth quarter reached 225.7 M€, a significant +9.2% growth c.....

BRIEF-Admedus on track to achieve forecast $21m in annual revenue

* Anticipates finishing year with sales considerably stronger than previous year

5th annual Breakthrough Prize – Science Superstars in three categories: life sciences, fundamental physics, and mathematics.

5th annual Breakthrough Prize – Science Superstars in three categories: life sciences, fundamental physics, and mathematics. Reporter: Aviva Lev-Ari, PhD, RN   December 05, 2016 Breakthrou...

Matching PubMed Articles

Validation of an Administrative Definition of ICU Admission Using Revenue Center Codes.

Describe the operating characteristics of a proposed set of revenue center codes to correctly identify ICU stays among hospitalized patients.

National survey of pediatric hospitalizations due to Kawasaki disease and coronary artery aneurysms in the USA.

Several studies revealed the epidemiology of Kawasaki disease-related hospitalizations among children in the USA and other countries. However, disparities of developing coronary artery aneurysms by ra...

The fourth annual meeting of the American College of Professional Neuropsychology (ACPN) poster roster, March 9-10, 2012, Las Vegas, Nevada.

Publication Rates of Abstracts Accepted to the 2010-2012 Annual Meetings of the North American Spine Society.

Retrospective review of conference abstracts.

Biohydrogen production from waste bread in a continuous stirred tank reactor: A techno-economic analysis.

Biohydrogen production from waste bread in a continuous stirred tank reactor (CSTR) was techno-economically assessed. The treating capacity of the H2-producing plant was assumed to be 2 ton waste brea...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement